Top

Endocrine

Published in:

Open Access 01-01-2020 | Metastasis | Meta-Analysis

Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis

Authors: Jing Yang, Yanping Gong, Shuping Yan, Hui Chen, Siqin Qin, Rixiang Gong

Published in: Endocrine | Issue 1/2020

Abstract

Background

The association between telomerase reverse transcriptase (TERT) promoter mutations and some clinical behaviors in thyroid cancer remains controversial and requires additional investigation. This study aimed to evaluate the association between TERT promoter mutations and clinical behaviors (including clinicopathological features and prognosis) in differentiated thyroid carcinomas (DTC).

Methods

We performed an up-to-date systematic review and current comprehensive meta-analysis. We searched three electronic databases for relevant studies. We used fixed- or random-effect models to calculate pooled estimated odds ratios (ORs) or standardized mean differences (SMDs) and corresponding 95% confidence intervals (CIs).

Results

We included 51 eligible studies incorporating 11,382 cases. Average frequencies of TERT promoter mutations in DTC, papillary (PTC), and follicular (FTC) thyroid carcinomas were 10.9%, 10.6%, and 15.1%, respectively. In DTC and PTC, TERT promoter mutations were significantly associated with sex, age, tumor size, vascular invasion, extrathyroidal extension, lymph node and distant metastases, advanced tumor, nodes, and metastasis (TNM) stage, persistence/recurrence, and disease-specific mortality. In FTC, TERT promoter mutations were significantly associated with age, distant metastases, advanced TNM stage, persistence/recurrence, and disease-specific mortality.

Conclusions

TERT promoter mutations could be considered as biomarkers assisting in risk stratification, prognostic prediction, and individualizing therapeutic options for DTC (PTC and FTC).

Available only for authorised users

N. Howlader, A.M. Noone, M. Krapcho, D. Miller, K. Bishop, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, A., Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin (eds), SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017

M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13, 184–199 (2013)PubMedPubMedCentral

R.K. Orosco, T. Hussain, K.T. Brumund, D.K. Oh, D.C. Chang, M. Bouvet, Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the surveillance, epidemiology, and end results database. Thyroid 25, 125–132 (2015)PubMedPubMedCentral

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)PubMedPubMedCentral

Y.S. Cong, J. Wen, S. Bacchetti, The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8, 137–142 (1999)PubMed

G. Aubert, P.M. Lansdorp, Telomeres and aging. Physiol. Rev. 88, 557–579 (2008)PubMed

S. Horn, A. Figl, P.S. Rachakonda, C. Fischer, A. Sucker, A. Gast, S. Kadel, I. Moll, E. Nagore, K. Hemminki, D. Schadendorf, R. Kumar, TERT promoter mutations in familial and sporadic melanoma. Science 339, 959–961 (2013)PubMed

F.W. Huang, E. Hodis, M.J. Xu, G.V. Kryukov, L. Chin, L.A. Garraway, Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013)PubMedPubMedCentral

P.J. Killela, Z.J. Reitman, Y. Jiao, C. Bettegowda, N. Agrawal, L.A.L.A. Diaz Jr, A.H. Friedman, H. Friedman, G.L. Gallia, B.C. Giovanella, A.P. Grollman, T.C. He, Y. He, R.H. Hruban, G.L. Jallo, N. Mandahl, A.K. Meeker, F. Mertens, G.J. Netto, B.A. Rasheed, G.J. Riggins, T.A. Rosenquist, M. Schiffman, Ie.M. Shih, D. Theodorescu, M.S. Torbenson, V.E. Velculescu, T.L. Wang, N. Wentzensen, L.D. Wood, M. Zhang, R.E. McLendon, D.D. Bigner, K.W. Kinzler, B. Vogelstein, N. Papadopoulos, H. Yan, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. PNAS 110, 6021–6026 (2013)PubMed

10.

X. Liu, G. Wu, Y. Shan, Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 12, 1637–1638 (2013)PubMedPubMedCentral

11.

J. Vinagre, A. Almeida, H. Pópulo, R. Batista, J. Lyra, V. Pinto, R. Coelho, R. Celestino, H. Prazeres, L. Lima, M. Melo, A.G. da Rocha, A. Preto, P. Castro, L. Castro, F. Pardal, J.M. Lopes, L.L. Santos, R.M. Reis, J. Cameselle-Teijeiro, M. Sobrinho-Simões, J. Lima, V. Máximo, P. Soares, Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013)PubMed

12.

X. Liu, J. Bishop, Y. Shan, S. Pai, D. Liu, A.K. Murugan, H. Sun, A.K. El-Naggar, M. Xing, Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr.-Relat. Cancer 20, 603–610 (2013)PubMedPubMedCentral

13.

R.J. Bell, H.T. Rube, A. Kreig, A. Mancini, S.D. Fouse, R.P. Nagarajan, S. Choi, C. Hong, D. He, M. Pekmezci, J.K. Wiencke, M.R. Wrensch, S.M. Chang, K.M. Walsh, S. Myong, J.S. Song, J.F. Costello, The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348, 1036–1039 (2015)PubMedPubMedCentral

14.

T. Liu, N. Wang, J. Cao, The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33, 4978–4984 (2014)PubMed

15.

X. Liu, S. Qu, R. Liu, C. Sheng, X. Shi, G. Zhu, A.K. Murugan, H. Guan, H. Yu, Y. Wang, H. Sun, Z. Shan, W. Teng, M. Xing, M. TERT, promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J. Clin. Endocrinol. Metab. 99, E1130–E1136 (2014)PubMedPubMedCentral

16.

M. Melo, A.G. da Rocha, J. Vinagre, R. Batista, J. Peixoto, C. Tavares, R. Celestino, A. Almeida, C. Salgado, C. Eloy, P. Castro, H. Prazeres, J. Lima, T. Amaro, C. Lobo, M.J. Martins, M. Moura, B. Cavaco, V. Leite, J.M. Cameselle-Teijeiro, F. Carrilho, M. Carvalheiro, V. Máximo, M. Sobrinho-Simões, P. Soares, TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 99, E754–E765 (2014)PubMedPubMedCentral

17.

M. Xing, R. Liu, X. Liu, A.K. Murugan, G. Zhu, M.A. Zeiger, S. Pai, J. Bishop, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J. Clin. Oncol. 32, 2718–2726 (2014)PubMedPubMedCentral

18.

M. Bullock, Y. Ren, C. O’Neill, A. Gill, A. Aniss, M. Sywak, S. Sidhu, L. Delbridge, D. Learoyd, F. de Vathaire, B.G. Robinson, R.J. Clifton-Bligh, TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin. Endocrinol. 85, 283–290 (2016)

19.

L. Jin, E. Chen, S. Dong, Y. Cai, X. Zhang, Y. Zhou, R. Zeng, F. Yang, C. Pan, Y. Liu, W. Wu, M. Xing, X. Zhang, O. Wang, BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: A study of 653 patients. Oncotarget 7, 18346–18355 (2016)PubMedPubMedCentral

20.

Y.S. Song, J.A. Lim, H.S. Min, M.J. Kim, H.S. Choi, S.W. Cho, J.H. Moon, K.H. Yi, D.J. Park, B.Y. Cho, Y.J. Park, Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. Eur. J. Endocrinol. 177, 465–473 (2017)PubMed

21.

D.T. Yin, K. Yu, R.Q. Lu, X. Li, J. Xu, M. Lei, H. Li, Y. Wang, Z. Liu, Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis. Clin. Endocrinol. 85, 299–305 (2016)

22.

C. Liu, Z. Liu, T. Chen, W. Zeng, Y. Guo, T. Huang, TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis. Sci. Rep. 6, 36990 (2016)PubMedPubMedCentral

23.

S.J. Kim, S.Y. Park, Y.J. Lee, E.K. Lee, S.K. Kim, T.H. Kim, Y.S. Jung, J. Ryu, J.P. Myong, K.W. Chung, Risk factors for recurrence after therapeutic lateral neck dissection for primary papillary thyroid cancer. Ann. Surg. Oncol. 21, 1884–1890 (2014)PubMed

24.

D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman; PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e100097 (2009)

25.

G.A. Wells, B. Shea, D. O’Connell, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (Ottawa: Ottawa Hospital Institute, 2018). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 10 Feb 2018

26.

N. Wang, T. Liu, A. Sofiadis, C.C. Juhlin, J. Zedenius, A. Höög, C. Larsson, D. Xu, TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 120, 2965–2979 (2014)PubMed

27.

D. de Biase, G. Gandolfi, M. Ragazzi, M. Eszlinger, V. Sancisi, M. Gugnoni, M. Visani, A. Paession, G. Casadei, C. Durante, G. Costante, R. Bruno, M. Torlontano, R. Paschke, S. Filetti, S. Piana, A. Frasoldati, G. Tallini, A. Ciarrocchi, TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid 25, 1013–1019 (2015)PubMed

28.

G. Gandolfi, M. Ragazzi, A. Frasoldati, S. Piana, A. Ciarrocchi, V. Sancisi, TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur. J. Endocrinol. 172, 403–413 (2015)PubMed

29.

J.R. George, Y.C. Henderson, M.D. Williams, D.B. Roberts, H. Hei, S.Y. Lai, G.L. Clayman, Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J. Clin. Endocrinol. Metab. 100, E1550–E1559 (2015)PubMedPubMedCentral

30.

M. Muzza, C. Colombo, S. Rossi, D. Tosi, V. Cirello, M. Perrino, S. De Leo, E. Magnani, E. Pignatti, B. Vigo, M. Simoni, G. Bulfamante, L. Vicentini, L. Fugazzola, Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol. Cell Endocrinol. 399, 288–295 (2015)PubMed

31.

E. Qasem, A.K. Murugan, H. Al-Hindi, M. Xing, M. Almohanna, M. Alswailem, A.S. Alzahrani, TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr. Relat. Cancer 22, 901–908 (2015)PubMed

32.

J.S. Bae, Y. Kim, S. Jeon, S.H. Kim, T.J. Kim, S. Lee, M.H. Kim, D.J. Lim, Y.S. Lee, C.K. Jung, Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagn. Pathol. 11, 21 (2016)PubMedPubMedCentral

33.

M.J. Jeon, W.G. Kim, S. Sim, S. Lim, H. Kwon, T.Y. Kim, Y.K. Shong, W.B. Kim, Low prevalence of somatic TERT promoter mutations in classic papillary thyroid carcinoma. Endocrinol. Metab. 31, 100–104 (2016)

34.

T.H. Kim, Y.E. Kim, S. Ahn, J.Y. Kim, C.S. Ki, Y.L. Oh, K. Kim, J.W. Yun, W.Y. Park, J.H. Choe, J.H. Kim, J.S. Kim, S.W. Kim, J.H. Chung, TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr. Relat. Cancer 23, 813–823 (2016)PubMed

35.

S.E. Lee, T.S. Hwang, Y.L. Choi, H.S. Han, W.S. Kim, M.H. Jang, S.K. Kim, J.H. Yang, Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) mutation-prevalent population. Thyroid 26, 901–910 (2016)PubMed

36.

J.K. Myung, B.K. Kwak, J.A. Lim, M.C. Lee, M.J. Kim, TERT promoter mutations and tumor persistence/recurrence in papillary thyroid cancer. Cancer Res. Treat. 48, 942–947 (2016)PubMed

37.

A. Nasirden, T. Saito, Y. Fukumura, K. Hara, K. Akaike, A. Kurisaki-Arakawa, M. Asahina, A. Yamashita, R. Tomomasa, T. Hayashi, A. Arakawa, T. Yao, In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. Virchows Arch. 469, 687–696 (2016)PubMed

38.

S.Y. Sohn, W.Y. Park, H.T. Shin, J.S. Bae, C.S. Ki, Y.L. Oh, S.W. Kim, J.H. Chung, Highly concordant key genetic alterations in primary tumors and matched distant metastases in differentiated thyroid cancer. Thyroid 26, 672–682 (2016)PubMed

39.

Y.S. Song, J.A. Lim, H. Choi, J.K. Won, J.H. Moon, S.W. Cho, K.E. Lee, Y.J. Park, K.H. Yi, Dj Park, J.S. Seo, Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 122, 1370–1379 (2016)PubMed

40.

J. Sun, J. Zhang, J. Lu, J. Gao, X. Ren, L. Teng, H. Duan, Y. Lin, X. Li, B. Zhang, Z. Liang, BRAF V600E and TERT promoter mutations in papillary thyroid carcinoma in Chinese patients. PLoS ONE 11, e0153319 (2016)PubMedPubMedCentral

41.

P. Boaventura, R. Batista, A. Pestana, M. Reis, A. Mendes, C. Eloy, M. Sobrinho-Simões, P. Soares, TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation. Eur. J. Endocrinol. 176, 49–55 (2017)PubMed

42.

S.Y. Hahn, T.H. Kim, C.S. Ki, S.W. Kim, S. Ahn, J.H. Shin, J.H. Chung, Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations. Oncotarget 8, 108946–108957 (2017)PubMedPubMedCentral

43.

M. Matsuse, T. Yabuta, V. Saenko, M. Hirokawa, E. Nishihara, K. Suzuki, S. Yamashita, A. Miyauchi, N. Mitsutake, TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. Sci. Rep. 7, 41752 (2017)PubMedPubMedCentral

44.

M. Melo, A. Gaspar da Rocha, R. Batista, J. Vinagre, M.J. Martins, G. Costa, C. Ribeiro, F. Carrilho, V. Leite, C. Lobo, J.M. Cameselle-Teijeiro, B. Cavadas, L. Pereira, M. Sobrinho-Simões, P. Soares, TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease. J. Clin. Endocrinol. Metab. 102, 1898–1907 (2017)PubMed

45.

N. Oishi, T. Kondo, T. Nakazawa, K. Mochizuki, T. Inoue, K. Kasai, I. Tahara, T. Yabuta, M. Hirokawa, A. Miyauchi, R. Katoh, Frequent BRAF V600E and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan. Endocr. Pathol. 28, 103–111 (2017)PubMed

46.

X. Shen, R. Liu, M. Xing, A six-genotype genetic prognostic model for papillary thyroid cancer. Endocr. Relat. Cancer 24, 41–52 (2017)PubMed

47.

B. Xu, R.M. Tuttle, M.M. Sabra, I. Ganly, R. Ghossein, Primary thyroid carcinoma with low-risk histology and distant metastases: clinicopathologic and molecular characteristics. Thyroid 27, 632–640 (2017)PubMedPubMedCentral

48.

X. Yang, J. Li, X. Li, Z. Liang, W. Gao, J. Liang, S. Cheng, Y. Lin, TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J. Nucl. Med. 58, 258–265 (2017)PubMed

49.

M. Argyropoulou, A.S. Veskoukis, P.M. Karanatsiou, A. Manolakelli, I. Kostoglou-Athanassiou, G. Vilaras, A. Karameris, K. Liadaki, Low prevalence of TERT promoter, BRAF and RAS mutations in papillary thyroid cancer in the Greek population. Pathol. Oncol. Res. (2018) https://doi.org/10.1007/s12253-018-0497-2. [Epub ahead of print]

50.

R. Bu, A.K. Siraj, S.P. Divya, Y. Kong, S.K. Parvathareddy, M. Al-Rasheed, K.A.S. Al-Obaisi, I.G. Victoria, S.S. Al-Sobhi, M. Al-Dawish, F. Al-Dayel, K.S. Al-Kuraya, Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. Int J. Cancer 142, 2028–2039 (2018)PubMed

51.

C. Colombo, M. Muzza, M.C. Proverbio, D. Tosi, D. Soranna, C. Pesenti, S. Rossi, V. Cirello, S. De Leo, N. Fusco, M. Miozzo, G. Bulfamante, L. Vicentini, S. Ferrero, A. Zambon, S. Tabano, L. Fugazzola, Impact of mutation density and heterogeneity on papillary thyroid cancer clinical features and remission probability. Thyroid 29, 237–251 (2019)PubMed

52.

A.C. Insilla, A. Proietti, N. Borrelli, E. Macerola, C. Niccoli, P. Vitti, P. Miccoli, F. Basolo, TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases. Oncol. Lett. 15, 2763–2770 (2018)PubMed

53.

J. Liang, W. Cai, D. Feng, H. Teng, F. Mao, Y. Jiang, S. Hu, X. Li, Y. Zhang, B. Liu, Z.S. Sun, Genetic landscape of papillary thyroid carcinoma in the Chinese population. J. Pathol. 244, 215–266 (2018)PubMed

54.

H. Ren, Y. Shen, D. Hu, W. He, J. Zhou, Y. Cao, Y. Mao, Y. Dou, W. Xiong, Q. Xiao, Y. Zhang, X. Su, Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag. Res. 10, 1005–1013 (2018)PubMedPubMedCentral

55.

D. Rusinek, A. Pfeifer, J. Krajewska, M. Oczko-Wojciechowska, D. Handkiewicz-Junak, A. Pawlaczek, J. Zebracka-Gala, M. Kowalska, R. Cyplinska, E. Zembala-Nozynska, M. Chekan, E. Chmielik, A. Kropinska, R. Lamch, B. Jurecka-Lubieniecka, B. Jarzab, A. Czarniecka, Coexistence of TERT promoter mutations and the BRAF V600E alteration and its impact on histopathological features of papillary thyroid carcinoma in a selected series of Polish patients. Int J. Mol. Sci. 19, pii: E2647 (2018)

56.

S. Watutantrige-Fernando, F. Vianello, S. Barollo, L. Bertazza, F. Galuppini, E. Cavedon, S. Censi, C. Benna, E.C. Ide, A. Parisi, D. Nacamulli, M. Iacobone, G. Pennelli, C. Mian, The Hobnail variant of Papillary Thyroid Carcinoma: clinical/molecular characteristics of a large monocentric series and comparison with conventional histotypes. Thyroid 28, 96–103 (2018)PubMed

57.

A.M. Poma, R. Giannini, P. Piaggi, C. Ugolini, G. Materazzi, P. Miccoli, P. Vitti, F. Basolo, A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. Endocr. Connect. 7, 124–132 (2018)PubMed

58.

K.S. Wong, S.E. Higgins, E. Marqusee, M.A. Nehs, T. Angell, J.A. Barletta, Tall cell variant of papillary thyroid carcinoma: impact of change in WHO definition and molecular analysis. Endocr. Pathol. 30, 43–48 (2019)PubMed

59.

A. Crescenzi, P. Trimboli, D.C. Modica, C. Taffon, L. Guidobaldi, S. Taccogna, A. Rainer, M. Trombetta, E. Papini, G. Zelano, Preoperative assessment of TERT promoter mutation on thyroid core needle biopsies supports diagnosis of malignancy and addresses surgical strategy. Horm. Metab. Res. 48, 157–162 (2016)PubMed

60.

I.J. Marques, M.M.Moura, R.Cabrera, A.E.Pinto, J.Simões-Pereira, C.Santos, F.D.Menezes, D.Montezuma, R.Henrique, M.R.Teixeira, V.Leite, B.M.Cavaco, Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas. Clin. Endocrinol. 87, 394–399 (2017).

61.

J. Lee, S. Jeong, C.R. Lee, C.R. Ku, S.W. Kang, J.J. Jeong, K.H. Nam, D.Y. Shin, W.Y. Chung, E.J. Lee, Y.S. Jo, GLI1 transcription factor affects tumor aggressiveness in patients with papillary thyroid cancers. Medicine 94, e998 (2015)PubMedPubMedCentral

62.

C. Tavares, M.J. Coelho, C. Eloy, M. Melo, A.G. da Rocha, A. Pestana, R. Batista, L.B. Ferreira, E. Rios, S. Selmi-Ruby, B. Cavadas, L. Pereira, M. Sobrinho Simões, P. Soares, NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr. Connect. 7, 78–90 (2018)PubMed

63.

G. Gandolfi, M. Ragazzi, D. de Biase, M. Visani, E. Zanetti, F. Torricelli, V. Sancisi, M. Gugnoni, G. Manzotti, L. Braglia, S. Cavuto, D.F. Merlo, G. Tallini, A. Frasoldati, S. Piana, A. Ciarrocchi, Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas. Oncotarget 9, 1813–1825 (2018)PubMed

64.

M.S. Dettmer, A. Schmitt, H. Steinert, D. Capper, H. Moch, P. Komminoth, A. Perren, Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr. Relat. Cancer 22, 419–429 (2015)PubMed

65.

T.H. Kim, C.S. Ki, H.S. Kim, K. Kim, J.H. Choe, J.H. Kim, J.S. Kim, Y.L. Oh, S.Y. Hahn, J.H. Shin, H.W. Jang, S.W. Kim, J.H. Chung, Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations. J. Clin. Endocrinol. Metab. 102, 1757–1764 (2017)PubMed

66.

L. Morandi, A. Righi, F. Maletta, P. Rucci, F. Pagni, M. Gallo, S. Rossi, L. Caporali, A. Sapino, R.V. Lloyd, S. Asioli, Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. Endocr. Relat. Cancer 24, 107–117 (2017)PubMed

67.

J.O. Paulsson, N. Mu, I. Shaobo, N. Wang, J. Zedenius, C. Larsson, C.C. Juhlin, TERT aberrancies—a screening tool for malignancy in follicular thyroid tumours. Endocr. Relat. Cancer 25, 723–733 (2018)PubMed

68.

R. Liu, J. Bishop, G. Zhu, T. Zhang, P.W. Ladenson, M. Xing, Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 3, 202–208 (2017)PubMed

69.

R. Liu, M. Xing, Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr. Relat. Cancer 21, 825–830 (2014)PubMedPubMedCentral

70.

M.C. Topf, Z.X. Wang, M. Tuluc, E.A. Pribitkin, TERT, HRAS, and EIF1AX mutations in a patient with follicular adenoma. Thyroid 28, 815–817 (2018)PubMed

71.

A. Proietti, C. Sartori, E. Macerola, N. Borrelli, G. Materazzi, P. Vitti, F. Basolo, Low frequengcy of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms. Virchows Arch. 471, 769–773 (2017)PubMed

72.

R.V. Lloyd, R.Y. Osamura, G. Klöppel, J. Rosai (Eds), WHO classification of tumours of endocrine organs WHO/IARC classification of tumours, 4th edn., 10. (France: International agency for Research on Cancer (IARC), 2017)

Title: Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis
Authors: Jing Yang
Yanping Gong
Shuping Yan
Hui Chen
Siqin Qin
Rixiang Gong
Publication date: 01-01-2020
Publisher: Springer US
Keyword: Metastasis
Published in: Endocrine / Issue 1/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02117-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Nonalcoholic fatty liver disease in women with polycystic ovary syndrome

Imbalanced testicular metabolism induced by thyroid disorders: New evidences from quantitative proteome

BET bromodomain inhibition suppresses adipogenesis in mice

In children with acquired hypothyroidism levothyroxine requirements may be significantly conditioned by the etiology of thyroid failure

Interobserver agreement and efficacy of consensus reading in Kwak-, EU-, and ACR-thyroid imaging recording and data systems and ATA guidelines for the ultrasound risk stratification of thyroid nodules

Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: A systematic review and meta-analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials